AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
Log in

NASDAQ:FPRXFive Prime Therapeutics Income Statement & Balance Sheet

$5.43
+0.13 (+2.45 %)
(As of 05/26/2020 09:16 AM ET)
Add
Compare
Today's Range
$5.26
Now: $5.43
$5.60
50-Day Range
$2.14
MA: $3.39
$5.43
52-Week Range
$1.75
Now: $5.43
$9.13
Volume311,890 shs
Average Volume405,966 shs
Market Capitalization$198.90 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78

Financials

Five Prime Therapeutics (NASDAQ:FPRX) Income Statement, Balance Sheet and Cash Flow Statement

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.